|
|
Post by peppy on May 10, 2017 16:48:37 GMT -5
|
|
|
|
Post by boytroy88 on May 10, 2017 16:51:41 GMT -5
*sigh*
|
|
|
|
Post by peppy on May 10, 2017 16:51:44 GMT -5
the label change is for a different class of insulin. That is huge. Forging ahead. what seems to have changed is the physicians seem to be coming around. From what I can see on the Television afrezza spots by local news.
Laura K: "And if you have a forward thinking endo" heh
|
|
|
|
Post by avi8torslc on May 10, 2017 16:52:48 GMT -5
UAE......is that our Middle east country? Know shortly
|
|
|
|
Post by boytroy88 on May 10, 2017 16:53:53 GMT -5
the label change is for a different class of insulin. Which is good but seems like everything else is just "wait and see"...again. |
|
|
|
Post by peppy on May 10, 2017 16:55:07 GMT -5
UAE......is that our Middle east country? Know shortly yes, we are going to zero in on the transcript there. vaguely sounded like we have it, it can not be announced.
|
|
|
|
Post by boytroy88 on May 10, 2017 16:55:15 GMT -5
UAE......is that our Middle east country? Know shortly They did mentioned sales to third party but in terms of cost only since it hasn't been dispersed...or did I hear it wrong? |
|
|
|
Post by seanismorris on May 10, 2017 16:56:30 GMT -5
I'm not sure that a "different" class of insulin is a big deal. It sounds like more of a marketing ploy, basically a repackaging of the "ultra" idea that got shot down.
|
|
|
|
Post by sophie on May 10, 2017 16:57:21 GMT -5
the label change is for a different class of insulin. Which is good but seems like everything else is just "wait and see"...again. If Novo is also producing an Ultra rapid insulin and they too get that designation, it could make the label change insignificant. As we're seeing now, being in the same class as RAA's is doing nothing for us because there are other options that docs like better with no reason to choose Afrezza over them. A saving grace would be if this other ultra rapid insulin behaves similarly and paves the way for an understanding of how Afrezza works, but even then, until a long term safety test is completed, I see little reason for a label change to improve sales if we're not the only drug in that class. |
|
|
|
Post by peppy on May 10, 2017 16:57:27 GMT -5
UAE......is that our Middle east country? Know shortly They did mentioned sales to third party but in terms of cost only since it hasn't been dispersed...or did I hear it wrong? the minute the replay is on, heh..... I think this thing will be bought tomorrow
|
|
|
|
Post by peppy on May 10, 2017 16:57:48 GMT -5
I'm not sure that a "different" class of insulin is a big deal. It sounds like more of a marketing ploy, basically a repackaging of the "ultra" idea that got shot down. it is huge
874,000 shares traded after hours. just looking. this thing is in play.
|
|
|
|
Post by seanismorris on May 10, 2017 16:58:09 GMT -5
The run up sounds like it was because of the "middle east" comment. Someone expected the deal to be done and announced on this call.
|
|
|
|
Post by sophie on May 10, 2017 16:58:41 GMT -5
UAE......is that our Middle east country? Know shortly yes, we are going to zero in on the transcript there. vaguely sounded like we have it, it can not be announced.
You'll probably have a greater sense than me after reading the transcript, but the impression I got was that nothing was finalized, but that Matt felt confident that it would go through. Kind of sounds like they are in the finalizing stages. |
|
|
|
Post by seanismorris on May 10, 2017 16:59:08 GMT -5
So, we can expect a correction down until the Middle East deal is announced.
|
|
|
|
Post by me on May 10, 2017 16:59:37 GMT -5
The run up sounds like it was because of the "middle east" comment. Someone expected the deal to be done and announced on this call. That's probably the most reasonable explanation of the price action the past few days. |
|
